Stockreport

aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update

aTyr Pharma, Inc.  (ATYR) 
PDF Enrollment completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data expected in the third quarter of 2025. Publication in European Res [Read more]